Basketball + Fourth of July + air conditioning = a great way to raise money for Down syndrome cognition research!
Our friend and Board Member Anthony Providenti hosts a Long Island tradition, a basketball tournament to benefit the LuMind Foundation. The event raised $4000 and the spirits of all of us here at LuMind – thanks to everyone who played, cheered and donated.
Here’s an article about the event:
Young and Hoary Battled at Sportime – Tournament benefited Down syndrome foundation
Need a reminder of how persuasive the promise of Ds cognition research can be? Take it from one of DSRTF’s supporting friends. “My name is Vittoria Aiello,” she writes, “and I am the proud mother of Federica, a 3-year old girl with Down syndrome.
“Since our daughter was born, my husband Massimiliano Albanese and I have been very active in advocating for the rights of people with Down syndrome. This past summer we decided we wanted to raise awareness about the importance of funding Down syndrome research, and started a fundraiser to benefit the Down Syndrome Research and Treatment Foundation (DRSTF). This fundraiser was a great success, not only because of the amount of money raised but also because of the awareness and significant interest this campaign raised among people from different walks of life.
“We started asking for donations from our friends and family and, slowly but consistently, our campaign grew beyond our relationship circle. In fact, we received numerous donations from people we barely knew. We were amazed by the empathy, solidarity, and humanity shown to us not only by family and friends, but also by simple acquaintances and people who happened to learn about our campaign from their family and friends — they joined this cause with incredible enthusiasm, involving, in turn, their family and friends.
“To us, our donors have not just given an amount of money. They have donated something more precious and less tangible than money: they have donated hope for a better future for people with Down syndrome.”
Our sincere gratitude goes out to Vittoria, Massimiliano, and their friends — and their friends…and beyond! — for believing in the importance of the work DSRTF promotes, for generously supporting it, and for spreading the word far and wide.
The sun was bright at New York’s Asphalt Green — but no brighter than the smiles on everyone who joined us for this year’s Romp for Research! 2013 marked the Romp’s eighth anniversary, and the joy was infectious as families came together to celebrate the accomplishments and the potential of our loved ones with Ds. With music, sports, games, food, and entertainment, the Romp gave us all a day to remember as it gave research a phenomenal boost: this year’s Romp raised over $175,000 to support cognition research. And if that weren’t enough to make us feel like dancing, this breezy look at the Romp certainly would:
We thank all the volunteers who keep the fun coming each year at the Romp, and who sustain DSRTF’s efforts through their time and their considerable talents, notably Anthony Providenti, Mary Costello, and Stephen Lazare, founding members of our Romp committee. And we loved meeting every one of you who came out that day to play. A tip of the rainbow clown wig to you all — see you at next year’s Romp!
Connecting Families and Individuals with DS to Researchers
We’re gratified and excited to pass along the news that the NIH has launched its national registry specifically for people with Down syndrome, DS-Connect. This centralized information clearinghouse has been created to facilitate communication among families, researchers, clinicians, and patient groups, and will be crucial, says DSRTF’s Chief Scientific Officer Dr. Michael Harpold, to facilitating and supporting new clinical studies and trials for the benefit of people with DS. We look forward to the enhanced information sharing it will allow, and we thank the NIH for its continued service to the DS community. Visit DS-Connect now!
Now here’s something truly refreshing!
L to R: Owen Killius, Ryan Taylor, Hope Taylor, friend and organizer Grace Killius, Charlie Killius, Ben Taylor
Our friend Jill Taylor, mother of Hope, writes:
Grace, one of my daughter Hope’s friends, ran a lemonade stand for DSRTF this past weekend and raised $157. How sweet and wonderful is that?! My daughter, Ryan, worked the stand with Grace the whole time in 98 degree heat. They told every buyer it was for Ds research.
My heart was FULL, to say the least.
Ours, too. We send our heartfelt thanks to Grace, Ryan, and the entire crew of helpers who generously gave their time and efforts to support the work we do. As Jill says, “It’s so representative of Ds touching typically developing kids, as well.” These kids are an inspiration — thank you all for being a real force for good.
A newly published study funded in part by DSRTF shows that an FDA-approved asthma drug already in use improves cognitive function in a mouse model of Down syndrome, providing evidence in support of a new therapeutic target, the beta-2 andregenic receptors in the hippocampus.
Stanford’s Dr. Ahmad Salehi
The drug, a bronchodilator called formoterol, was shown in the study to strengthen nerve connections in the hippocampus, a brain center used for spatial navigation, paying attention and forming new memories, the study said. It also improved contextual learning, in which the brain integrates spatial and sensory information. A high dosage of the drug was administered over a period no longer than two weeks, resulting in notable improvements in the mice’s neuronal structures. “The fact that such a short period of giving medication can make these neurons much more complex is very interesting,” said Stanford University’s Ahmad Salehi, MD, Ph.D., the study’s lead author and a DSRTF grant recipient.
Salehi called the study, published July 2 in Biological Psychiatry, an “initial proof-of-concept,” cautioning that the dose he and his colleagues used was higher than that used in asthma treatment and cannot be safely adminstered to human patients without the risk of significant side effects. Nonetheless, these results hold great promise for new classes of drugs to target this receptor, with the goal of improving cognition in people with Down syndrome.
DSRTF is continuing support for this exciting research, and will provide updates on its progress.